CRLF2 Inhibitors
CRLF2 inhibitors represent a unique class of compounds specifically designed to target the cytokine receptor-like factor 2 (CRLF2), a protein implicated in various signaling pathways that govern cell growth and differentiation. CRLF2 is part of the class II cytokine receptor family and plays a significant role in the immune response and hematopoiesis. The inhibitors in this class interact with CRLF2, disrupting its normal function and altering downstream signaling pathways. This modulation can influence cellular behaviors such as proliferation, survival, and immune modulation, making CRLF2 a focal point for research into various biological processes.
The design of CRLF2 inhibitors typically involves the identification of small molecules or biologics that can effectively bind to specific domains of the CRLF2 protein. These inhibitors often exhibit structural diversity, utilizing various scaffolds that promote strong interactions with the receptor. Through techniques such as structure-based drug design and high-throughput screening, researchers are able to optimize these compounds for enhanced binding affinity and selectivity. Detailed mechanistic studies are conducted to elucidate how these inhibitors influence CRLF2-mediated signaling and cellular responses. Understanding the molecular interactions between CRLF2 inhibitors and the target receptor is crucial for uncovering the broader implications of CRLF2 in cellular homeostasis and its potential roles in disease states. As such, CRLF2 inhibitors serve as important tools in dissecting the functional role of this protein in cellular dynamics.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone can downregulate CRLF2 expression through the suppression of inflammatory cytokine signaling, leading to decreased transactivation of genes associated with immune responses. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid may diminish CRLF2 expression by binding to its nuclear receptors, which then bind to retinoic acid response elements in the regulatory regions of genes, altering their transcription. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A may lead to a decrease in CRLF2 expression by inhibiting calcineurin, subsequently preventing the activation of NFAT, a transcription factor involved in cytokine gene transcription. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic Acid could contribute to a reduction in CRLF2 expression by impeding the proliferation of B- and T-lymphocytes, which are often the cells overexpressing CRLF2 in leukemia. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may cause a reduction in CRLF2 expression by inhibiting DNA methyltransferase, which could result in the hypomethylation of the CRLF2 gene promoter, altering gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may suppress CRLF2 expression by obstructing the mTOR pathway, known for its role in controlling translation and cell growth, which is critical for lymphocyte function and proliferation. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
FK-506 could contribute to lower CRLF2 expression by binding to the immunophilin FKBP-12, creating a complex that inhibits calcineurin, and thus reducing T-cell activation and cytokine transcription. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea may curtail CRLF2 expression by arresting the cell cycle and depleting deoxyribonucleotide pools, leading to decreased DNA synthesis and repair, affecting gene transcription. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine has the potential to attenuate CRLF2 expression by interfering with endosomal acidification and lysosomal activity, which could disrupt cellular processing and signaling related to cytokine receptors. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate may truncate CRLF2 expression by acting as a folate analog, inhibiting dihydrofolate reductase, leading to reduced availability of thymidine and purine, which are necessary for DNA and RNA synthesis. | ||||||